Hepatitis B virus inhibits apolipoprotein A5 expression through its core gene

Lipids in Health and Disease

Volumn 15, Issue 1, 2016, Pages 1-6

  Zhu, Chengliang ^a   Gao, Guosheng ^b   Song, Hui ^c   Xu, Fengxia ^c   Wu, Kailang ^d   Liu, Xinghui ^c  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Ningbo No2 Hospital   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d WUHAN UNIVERSITY   (China)

Author keywords

Apolipoprotein A5; Expression; Hepatitis B virus

Indexed keywords

APOLIPOPROTEIN A5; CORE PROTEIN; MESSENGER RNA; APOA5 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; CORE GENE; FEMALE; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HEPG2 CELL LINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROTEIN EXPRESSION; VIRUS GENE; VIRUS GENOME; AGED; BIOSYNTHESIS; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEP-G2 CELL LINE; LIPID METABOLISM; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; VIROLOGY;

AGED; APOLIPOPROTEIN A-V; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; LIPID METABOLISM; LIPID METABOLISM DISORDERS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TRANSFECTION;

EID: 84991101869     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-016-0340-2     Document Type: Article

References (25)

1. Bitton Alaluf M, Shlomai A. New therapies for chronic hepatitis B. Liver Int. 2016;36:775-82.
2. Geng M, Xin X, Bi LQ, Zhou LT, Liu XH. Molecular mechanism of hepatitis B virus X protein function in hepatocarcinogenesis. World J Gastroenterol. 2015;21:10732-8.
3. Wu Q, Xu C, Li J, Li L, Yan G, Yue L, Zeng Y, Huang H, Deng G, Wang Y. Evolution and mutations of hepatitis B virus quasispecies in genotype B and C during vertical transmission. J Med Virol. 2016;88:1018-26.
4. O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem. 2005;51:351-9.
5. Hsu CS, Liu CH, Wang CC, Tseng TC, Liu CJ, Chen CL, Chen PJ, Chen DS, Kao JH. Impact of hepatitis B virus infection on metabolic profiles and modifying factors. J Viral Hepat. 2012;19:e48-57.
6. Li W, Liu Y, Mukhtar MM, Gong R, Pan Y, Rasool ST, Gao Y, Kang L, Hao Q, Peng G, et al. Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. PLoS One. 2008;3, e1985.
7. Wu KL, Zhang X, Zhang J, Yang Y, Mu YX, Liu M, Lu L, Li Y, Zhu Y, Wu J. Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment. Virus Res. 2005;112:100-7.
8. Zhu C, Zhang R, Liu L, Rasool ST, Mu Y, Sun W, Hao Q, Liu F, Zhu Y, Wu J. Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro. Clin Immunol. 2009;131:92-7.
9. Yan YL, Qiu B, Hu LJ, Jing XD, Liu YJ, Deng SB, Du JL, She Q. Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: A systematic review and meta-analysis. Eur J Clin Pharmacol. 2013;69:2001-9.
10. Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: Potential sites for therapeutic targets. Metabolism. 2013;62:479-91.
11. Luo L, Pu X, Wang Y, Xu N. Impaired plasma lipid profiles in acute hepatitis. Lipids Health Dis. 2010;9:5.
12. Aizawa Y, Seki N, Nagano T, Abe H. Chronic hepatitis C virus infection and lipoprotein metabolism. World J Gastroenterol. 2015;21:10299-313.
13. Myerson M, Malvestutto C, Aberg JA. Management of lipid disorders in patients living with HIV. J Clin Pharmacol. 2015;55:957-74.
14. Wang CC, Tseng TC, Kao JH. Hepatitis B virus infection and metabolic syndrome: Fact or fiction? J Gastroenterol Hepatol. 2015;30:14-20.
15. Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, Yee LJ, Virahep CSG. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology. 2010;52:854-63.
16. Zhu C, Zhang R, Liu D, Mukhtar MM, Liu W, Peng G, Wang K, Hao Q, Xu Y, Liu F, et al. Association of functional polymorphism of ApoB promoter with hepatitis C virus infection. Clin Chim Acta. 2009;401:124-7.
17. Guerra CT, Caini P, Giannini C, Giannelli F, Gragnani L, Petrarca A, Solazzo V, Monti M, Laffi G, Zignego AL. Effect of chronic hepatitis C virus infection on inflammatory lipid mediators. Dig Liver Dis. 2007;39 Suppl 1:S76-82.
18. Wang FB, Zhu CL, Liu X, Gao GS. HBV inhibits apoB production via the suppression of MTP expression. Lipids Health Dis. 2011;10:207.
19. Gu JG, Zhu CL, Cheng DZ, Xie Y, Liu F, Zhou X. Enchanced levels of apolipoprotein M during HBV infection feedback suppresses HBV replication. Lipids Health Dis. 2011;10:154.
20. Jiang W, Zheng L, Yang Q, Huang Z, Wang X. Investigation into the effect of hepatitis B virus on apoliprotein A1 expression and its mechanism. Lipids Health Dis. 2014;13:130.
21. Wang Y, Hao J, Liu X, Wang H, Zeng X, Yang J, Li L, Kuang X, Zhang T. The mechanism of apoliprotein A1 down-regulated by Hepatitis B virus. Lipids Health Dis. 2016;15:64.
22. Huang XS, Zhao SP, Zhang Q, Bai L, Hu M. Association of plasma apolipoprotein AV with lipid profiles in patients with acute coronary syndrome. Atherosclerosis. 2009;204:e99-102.
23. Qu S, Perdomo G, Su D, D'Souza FM, Shachter NS, Dong HH. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice. J Lipid Res. 2007;48:1476-87.
24. Bilora F, Campagnolo E, Rinaldi R, Rossato A, Arzenton M, Petrobelli F. Carotid and femoral atherosclerosis in chronic hepatitis C: A 5-year follow-up. Angiology. 2008;59:717-20.
25. Ciccone MM, Principi M, Ierardi E, Di Leo A, Ricci G, Carbonara S, Gesualdo M, Devito F, Zito A, Cortese F, Scicchitano P. Inflammatory bowel disease, liver diseases and endothelial function: Is there a linkage? J Cardiovasc Med (Hagerstown). 2015;16:11-21.